Brian Reed: Hey — did you get a chance to look at the Lilly release this morning?
Eliza Ward: Yeah, just finished it. The TRIUMPH data.
Brian Reed: So — Eli Lilly, July 23rd, drops the Phase 3 top-line results for retatrutide and says they're filing a BLA with the FDA in Q1 2027. And the headline weight loss number is... up to approximately 30%.
Eliza Ward: Thirty percent. That's — wait, I've been watching retatrutide since the Phase 2 readout and even then I didn't expect that number to survive into Phase 3.
Brian Reed: Right — and the thing I can't quite get past is "up to approximately." That's doing a lot of work in that sentence. Up to thirty, from a trial that enrolled over 5,800 people across four separate arms. We don't know which dose, which timepoint, which patients.
Eliza Ward: No, that's — actually that's the right question to sit with. Because tirzepatide, which is Lilly's own approved dual agonist, was tracking around 22% in real-world use. So 30 versus 22 looks like a big jump. But different trials.
Brian Reed: Different populations, different everything.
Eliza Ward: Right. And the BLA filing is Q1 2027 — that's the plan as of today. What we actually don't know yet is how the FDA review timeline plays out from there.
Brian Reed: The timeline part I get — but the number itself, the 30%, that's where I keep getting stuck. Because think about it like a car dealership advertising "up to 60 miles per gallon." That's real. That's achievable. On a flat highway, no AC, optimal conditions. But it's not your commute.
Eliza Ward: That's exactly the gap. Phase 2 — confirmed number — was 24% mean body weight reduction at 48 weeks, highest dose. That's the average. The 30% in TRIUMPH Phase 3 is "up to approximately." Those are not the same sentence.
Brian Reed: And Lilly hasn't released which dose hits 30%, or at what timepoint, or which patient subset.
Eliza Ward: Right — so CNBC runs "Eli Lilly obesity drug cuts weight by 30%" and... wait, who reads that as a ceiling? Nobody. Every patient reads that as "I will lose 30%."
Brian Reed: And every investor prices in peak efficacy instead of — I mean, the typical patient in a real population probably lands somewhere closer to that Phase 2 mean. Which is still remarkable, genuinely, but it's not 30.
Eliza Ward: And the comparison to tirzepatide and semaglutide — there's no head-to-head trial. None exists. What there is, is a 2026 meta-analysis by Caquetti that stacks TRIUMPH data against SURMOUNT data, but those are different trial designs, different populations, different endpoints.
Brian Reed: So the "retatrutide beats tirzepatide" read is — that's inference, not evidence.
Eliza Ward: It's narrative. Informed narrative, maybe, but — actually no, let me be precise. The Caquetti meta-analysis is real, the methodological limits are also real, and neither Lilly nor the coverage is flagging those limits. That's what bothers me.
Brian Reed: The drug might genuinely be the best thing in this class. The data might hold up. But the number people are walking around with right now — 30% — is the ceiling on the best day, and we don't even know whose day that was.
Eliza Ward: And that ceiling problem bleeds straight into the benefits story — which is where I think the coverage is actually getting something wrong.
Brian Reed: The knee pain and sleep apnea numbers.
Eliza Ward: Exactly those. TRIUMPH-1 at 80 weeks — triglycerides down up to 41%, non-HDL cholesterol down 24.2%, systolic blood pressure down 12.3 millimeters of mercury. And nested inside the TRIUMPH trials: sleep apnea severity reduced up to 60.6%, knee osteoarthritis pain down 73.1%. And the take circulating is — this proves the glucagon receptor is doing something structurally different from what tirzepatide does. That's the wrong read.
Brian Reed: Yeah — I want to stress-test that. Because imagine a 52-year-old, bad knees, sleep apnea, loses 28% of her body weight on any effective drug. Any drug. Her sleep scores improve. Her knee pain drops. That's not a third receptor. That's physics.
Eliza Ward: Right, and — wait, the mechanistic story isn't nothing. Glucagon receptor activation does shift toward hepatic fat oxidation and increased energy expenditure. That is genuinely distinct from tirzepatide's dual GLP-1 and GIP agonism on paper. But — the trial design can't separate that effect from the weight loss effect. Those two things are happening simultaneously and nobody's pulled them apart.
Brian Reed: So the mechanism might be different. The outcomes might look identical to what extreme weight loss produces anyway.
Eliza Ward: That's the unresolved question. And Lilly intends to file for knee OA and sleep apnea separately — but those are stated intentions as of July 23rd, not confirmed simultaneous submissions. There's a real difference there.
Brian Reed: So the coverage is treating "the glucagon receptor explains the 73% knee number" as established — when actually, I mean, we'd need a trial that holds weight loss constant across arms and varies the receptor target. That trial doesn't exist.
Eliza Ward: It doesn't. And that question stays open until someone runs it. Which — actually the filing timeline matters for patients in a significant way we should get into.
Brian Reed: Right — and the filing timeline is exactly where that gap between 'milestone' and 'available' becomes real. Q1 2027 BLA submission, standard FDA review runs nine to twelve months, so you're looking at a decision — not approval, a decision — late 2027 at earliest. Probably 2028.
Eliza Ward: Which Lilly doesn't correct. Shareholders hear '2027.' Patients hear '2027.' Those are not the same event.
Brian Reed: And even approval isn't access. Tirzepatide — approved, on market, two years in — still has manufacturing supply constraints. Someone's rheumatologist right now is telling them Zepbound is backordered. So what does retatrutide's approval actually mean for the person sitting in that office?
Eliza Ward: Probably nothing immediate. Lilly would be ramping manufacturing for a drug that isn't approved yet — and they already haven't fully solved that for tirzepatide.
Brian Reed: Then there's the insurer question. Semaglutide is already running close to $1,300 a month. Retatrutide's probably more. And obesity still isn't treated as a disease by a huge slice of American plan designs. Cigna, United — formulary review alone could add another year.
Eliza Ward: So the BLA filing is — I mean, it's a real regulatory milestone, it matters commercially, but it's not the patient story. That's the clarity problem.
Brian Reed: And meanwhile — hang on, because this is the part that genuinely surprised me — there's already a compound behind retatrutide. VRX-0075. Quintuple agonist. GLP-1, GIP, glucagon, amylin, calcitonin. 2026 preclinical data in obese rats showed greater weight loss than retatrutide. Now — that's rats, that's early, I want to be clear that's speculation territory.
Eliza Ward: Wait — five receptors?
Brian Reed: Five. And if Novo Nordisk or someone else gets to a comparable clinical result before retatrutide even clears FDA review — actually, we don't know who's behind VRX-0075 yet — but the window retatrutide is filing into might be a lot more crowded by late 2028 than the current coverage is pricing in.
Eliza Ward: And that's — actually that's where the TRIUMPH data package lands for me. Strong trial, real numbers, BLA on track. But the distance between Q1 2027 filing and a patient actually filling a prescription is... I mean, nobody's closed that gap yet. Lilly hasn't. The coverage hasn't. VRX-0075 being five receptors deep in preclinical while retatrutide is still waiting on an FDA decision — that's not nothing.
Brian Reed: Will retatrutide reach patients at meaningful scale before something like VRX-0075, or whatever comes next, makes its own clinical case? Because late 2028, realistically, the field looks different. And I don't know the answer. I don't think anyone does right now.
Eliza Ward: No. Anyone telling you they do is getting ahead of the evidence.
Brian Reed: Manufacturing, formulary coverage, competitive timing — three separate problems, none of them pharmacology.
Eliza Ward: Watch the BLA. Watch whether Lilly files on schedule in Q1 2027. That's the next concrete thing. Everything else is still inference.
